ABSTRACT
Tamoxifen, a nonsteroidal antiestrogen, was first approved by the Food and Drug Administration for the treatment of patients with breast cancer in 1978. Large clinical trials involving over 75,000 patients have demonstrated an improved recurrence-free and overall survival benefit in both pre-and postmenopausal women. Long-term adjuvant tamoxifen is the endocrine treatment of choice for selected patients with breast cancer, and there are currently large-scale trials to evaluate its role as a chemopreventative agent in healthy women at risk for breast cancer. One of the most significant
complications of long-term tamoxifen use is the possible development of endometrial cancer.
